Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

被引:84
作者
Mannucci, E [1 ]
Ognibene, A [1 ]
Cremasco, F [1 ]
Bardini, G [1 ]
Mencucci, A [1 ]
Pierazzuoli, E [1 ]
Ciani, S [1 ]
Fanelli, A [1 ]
Messeri, G [1 ]
Rotella, CM [1 ]
机构
[1] Univ Florence, Dept Clin Pathophysiol, Chair Metab Dis & Diabetol, Endocrinol Sect, I-50134 Florence, Italy
关键词
euglycaemic hyperinsulinaemic clamp; glucagon-like peptide-1; leptin; obesity; Type 2 diabetes mellitus;
D O I
10.1046/j.1464-5491.2000.00367.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To assess differences in circulating leptin and glucagon-like peptide (GLP)-1 concentrations before and after an oral glucose load, in euglycaemic and isoinsulinaemic conditions, between obese patients with and without Type 2 diabetes mellitus. Methods Ten male obese (body mass index (BMI) > 30 kg/m(2)) patients with Type 2 diabetes and 20 matched non-diabetic subjects were studied. Leptin, GLP-1(7-36)amide and GLP-1(7-37) concentrations were measured 0, 30, 60, and 90 min after a 50-g oral glucose load administered 90 min after the beginning of a euglycaemic hyperinsulinaemic clamp. Results GLP-1(7-36)amide concentrations before the glucose load were significantly lower in diabetic patients than in controls (median (quartiles): 50.5 (44.7-53.2) vs. 128.7(100-172.5) pg/ml; P < 0.01), while no difference was observed in baseline GLP-1(7-37). In non-diabetic subjects, GLP-1(7-36)amide and GLP-1(7-37) concentrations increased significantly after the oral glucose load, while no glucose-induced increase in GLP-1 concentration was observed in diabetic patients. GLP-1(7-36)amide at 30, 60, and 90 min, and GLP-1(7-37) at 30 min, of the glucose challenge, were significantly lower in diabetic patients. Leptin concentrations were not significantly different in diabetic patients when compared to non-diabetic subjects, and they did not change after the oral glucose load. Discussion Leptin concentrations are not significantly modified in obese Type 2 diabetic patients. GLP-1(7-36)amide baseline concentrations are reduced in Type 2 diabetes; moreover, diabetic subjects show an impaired response of GLP-1 to oral glucose in euglycaemic, isoinsulinaemic conditions. This impairment, which is not the result of differences in glycaemia or insulinaemia during assessment, could contribute to the pathogenesis of hyperglycaemia in Type 2 diabetes mellitus.
引用
收藏
页码:713 / 719
页数:7
相关论文
共 30 条
[1]   Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus [J].
Ahren, B ;
Larsson, H ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :473-478
[2]  
Alberti KG, 1998, DIABETIC MED, V15, P593, DOI [10.1002/(SICI)1096-9136(199807, DOI 10.1002/(SICI)1096-9136(199807]
[3]  
Byrne MM, 1996, DIABETIC MED, V13, P854, DOI 10.1002/(SICI)1096-9136(199610)13:10<854::AID-DIA262>3.0.CO
[4]  
2-E
[5]   GLUCAGON-LIKE PEPTIDE-1 ENHANCES GLUCOSE-TOLERANCE BOTH BY STIMULATION OF INSULIN RELEASE AND BY INCREASING INSULIN-INDEPENDENT GLUCOSE DISPOSAL [J].
DALESSIO, DA ;
KAHN, SE ;
LEUSNER, CR ;
ENSINCK, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) :2263-2266
[6]  
DEFRONZO RA, 1979, AM J PHYSIOL, V237, P214
[7]  
DUPRE J, 1995, DIABETES, V44, P623
[8]   Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39 [J].
Edwards, CMB ;
Todd, JF ;
Mahmoudi, M ;
Wang, ZL ;
Wang, RM ;
Ghatei, MA ;
Bloom, SR .
DIABETES, 1999, 48 (01) :86-93
[9]   Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic [J].
Freyse, EJ ;
Knospe, S ;
Becher, T ;
El Hag, O ;
Göke, B ;
Fischer, U .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (01) :134-137
[10]   HYPERSECRETION OF TRUNCATED GLUCAGON-LIKE PEPTIDE-1 AND GASTRIC-INHIBITORY POLYPEPTIDE IN OBESE PATIENTS [J].
FUKASE, N ;
IGARASHI, M ;
TAKAHASHI, H ;
MANAKA, H ;
YAMATANI, K ;
DAIMON, M ;
TOMINAGA, M ;
SASAKI, H .
DIABETIC MEDICINE, 1993, 10 (01) :44-49